Sandeep Laumas, M.D.
Executive Chairman
Sandeep Laumas
Dr. Laumas founded Bearing Circle Capital and has served as its Managing Director since August 2007. Dr. Laumas began his career at Goldman Sachs & Co. in 1996 as an equity analyst in the healthcare investment banking division working on mergers, acquisitions and corporate finance transactions before transitioning to the healthcare equity research division. After leaving Goldman Sachs in 2000, Dr. Laumas moved to the buyside as an analyst at Balyasny Asset Management from 2001 to 2003. Dr. Laumas was a Managing Director of North Sound Capital from 2003 to 2007, where he was responsible for the global healthcare investment portfolio. Dr. Laumas serves as an independent director on the board of directors of Bioxcel Therapeutics, Inc. (NASDAQ: BTAI) since August 2017.  He also served on the board of directors of SRL Pvt. Ltd., one of southeast asia’s largest clinical laboratory service company from February 2011-2012 and a member of the board of director of Parkway Holdings Ltd. (Singapore) (acquired by IHH Healthcare for $3 Billion: SGX: IHH) from May to August 2010. Dr. Laumas received his A.B. in Chemistry from Cornell University in 1990, M.D. from Albany Medical College in 1995 with a research gap year at the Dana-Farber Cancer Institute and completed his medical internship in 1996 from the Yale University School of Medicine.
Chairman of the Board
    Christopher P. Prior, Ph.D.
    Chief Executive Officer
    Christopher P. Prior, Ph.D.
    Dr. Prior is a recognized industry leader both as a developer of important new therapeutics and as an accomplished serial entrepreneur. Over the course of his 30-year career, he has generated more than 25 INDs and achieved four product approvals. In addition, he founded, built-up and sold two companies (Principia, BioRexis) in deal values exceeding $0.5 Billion. Chris joined Innovate in 2015 as Chief Executive Officer. Chris received a B.Sc. (honors) in chemistry from the University of London, a Ph.D. in biochemistry from Columbia University in New York City and a research fellowship at The Rockefeller Medical Institute (New York). Chris is a member of the New York Academy of Sciences and is the author of numerous publications and patents focused on the development of therapeutics.
      Jay P. Madan, M.S.
      Founder, President and Chief Business Officer
      Jay P. Madan
      Mr. Madan founded Innovate Biopharmaceuticals in 2013 and has spent more than two decades in life sciences/biotech as a leader in M&A, technology transfer, cross border licensing and project development.  Mr. Madan’s experience in working across multiple teams at Reliance Life Sciences, Millipore, Baxter, Dade Behring, and Goodwin led him to develop a global network of healthcare professionals. He was the VP of Business Development at Reliance Biopharmaceuticals Pvt. Ltd. part of Reliance Industries Ltd., India’s largest conglomerate. Both at Reliance and Goodwin, he was focused on the development of their contract manufacturing businesses. Mr. Madan holds a Bachelor of Chemical Engineering from University of Mumbai and an M.S. in Chemical Engineering from Washington State University.
      Financial Expert
        June S. Almenoff, MD., Ph.D., F.A.C.P.
        Chief Operating Officer and Chief Medical Officer
        June S. Almenoff

        Dr. June Almenoff joined Innovate Biopharmaceuticals in 2018, bringing expertise in early and late stage product development, gastrointestinal therapeutics and business leadership.

        Dr. Almenoff was previously President and Chief Medical Officer at Furiex Pharmaceuticals where during her 4-year tenure the company's valuation increased ~10-fold, culminating in its acquisition by Actavis plc (now Allergan) for more than $1.2B in 2014. Furiex's lead product, eluxadoline (Viberzi R), a novel gastrointestinal drug, is approved in both the US and EU. Prior to joining Furiex, Dr. Almenoff held various positions of increasing responsibility at GlaxoSmithKline PLC. During her 12 years at GSK she was a Vice-President in the Clinical Safety organization, chaired a PhRMA-FDA working group and worked in scientific licensing. Dr. Almenoff also led the development of pioneering systems for minimizing risk in drug development, which has been widely adopted by industry and regulators.

        Dr. Almenoff is on the Board of Directors of RDD Pharma, a private, GI clinical stage biopharma company, serving as Executive Chair from 2015 to 2018. She serves on the Boards of Directors of Tigenix NV since 2016, Brainstorm Therapeutics since 2017, and Ohr Pharmaceutical since 2013. Dr. Almenoff also serves on the investment advisory board of the Harrington Discovery Institute. She has recently been a consultant and advisor to numerous biopharma companies in the areas of translational medicine, clinical development and commercial strategy in product development.

        Dr. Almenoff received her B.A. cum laude from Smith College, graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine and completed post-graduate medical training at Stanford University Medical Center (Internal Medicine, Infectious Diseases). Dr. Almenoff served on the faculty of Duke University School of Medicine, is an adjunct Professor at Duke and is a Fellow of the American College of Physicians.

          Kendyle Woodard, MBA
          Co-founder and Executive Vice President, Corporate Affairs

          Ms. Woodard co-founded Innovate Biopharmaceuticals in 2013 and has more than 15 years in business operations and marketing supporting startups, non-profits, manufacturers, and consulting companies. Ms. Woodard oversees the company’s operations and investor relations. She was the vice president of iBiotech working with clients on technology development, operations, marketing, and business development. Ms. Woodard assisted in the management and operations of several startup companies and with the commercialization of university technologies. As the Director of Marketing for the NC Biotechnology Center she positioned North Carolina as a world leader in life sciences to support the state’s economic development initiatives. Ms. Woodard earned her Bachelor of Science degree, magna cum laude, in international business and marketing from University of South Alabama and was awarded her Master of Business Administration degree, cum laude, from North Carolina State University. Ms. Woodard co-founded the Triangle chapter of Net Impact, is a past board member of the Women in Bio Triangle chapter, and currently serves as board chair of Adaptive Risk Systems, Inc.. Ms. Woodard is also a member of BIO’s Technology Transfer Committee.

            Copyright West LLC. Minimum 15 minutes delayed.